BROOKS.NS Brooks Laboratories NSE up 43.84% after hours Apr 2026: INR 72.90

BROOKS.NS stock surged 43.84% in after-hours trade on 06 Apr 2026, finishing at INR 64.05 on the NSE in India after a heavy volume spike of 806,197 shares. The move followed an intraday high of INR 64.05 from an open of INR 56.25 and a previous close of INR 44.53. Traders flagged the jump amid sector rotations in Healthcare and unusually strong relative volume versus the 50-day average. This after-hours surge places Brooks Laboratories Limited back in focus for short-term momentum and analyst attention.

Price action and volume: BROOKS.NS stock after-hours jump

BROOKS.NS stock closed after hours at INR 64.05, up 43.84% from the prior close of INR 44.53. Volume accelerated to 806,197 shares versus an average of 92,900, a relative volume of 10.06, signaling heavy participation. The intraday range was INR 54.56 to INR 64.05, suggesting buyers dominated late session flows.

Fundamentals snapshot: valuation and profitability for BROOKS.NS stock

Brooks Laboratories Limited trades at a trailing PE of 7.26 with EPS of 7.35 and market cap of INR 1,572,427,898. Price-to-book is 1.36 and price-to-sales is 1.77, while return on equity is strong at 23.29%. These metrics show value-style valuation within the Healthcare sector but modest free cash flow, with free cash flow per share at -0.13.

Meyka AI grade and analyst view for BROOKS.NS stock

Meyka AI rates BROOKS.NS with a score out of 100: 74.59 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects attractive valuation, solid ROE, but notes cash flow volatility and a wide 52-week range (INR 36.30 to INR 164.02).

Technicals and sector context for BROOKS.NS stock

Technically, momentum is mixed: RSI sits at 46.78 and ADX at 43.67 implying a strong trend but negative short-term momentum indicators. The 50-day average is INR 62.40 and the 200-day average is INR 108.62, indicating recent strength but longer-term downtrend. Healthcare sector returns have lagged broader markets, which may explain rotation-driven moves into selected drug manufacturers.

Risks and catalysts affecting BROOKS.NS stock

Key risks include concentrated revenue streams from contract manufacturing and a high days sales outstanding at 103.53 days. Upcoming catalysts include the earnings announcement on 26 May 2026 and any contract wins or regulatory updates. The company’s low debt-to-equity of 0.07 limits leverage risk but weak free cash flow raises liquidity watchpoints.

Price forecast and short-term targets for BROOKS.NS stock

Meyka AI’s forecast model projects a monthly level of INR 72.90 and a yearly target of INR 139.11. Against the current price of INR 64.05, the monthly projection implies an upside of 13.81% and the yearly projection implies 117.19% upside. Forecasts are model-based projections and not guarantees; they reflect scenario-weighted outcomes from Meyka AI’s analytics.

Final Thoughts

BROOKS.NS stock showed a dramatic after-hours spike on 06 Apr 2026, closing at INR 64.05 with outsized volume of 806,197 shares. The move reopens a value-versus-growth debate: the company trades at a low trailing PE of 7.26 and strong ROE of 23.29%, yet free cash flow remains negative on a per-share basis. Meyka AI’s model projects a monthly level of INR 72.90 (implied upside 13.81%) and a yearly target of INR 139.11 (implied upside 117.19%) versus the current price. Our proprietary grade is B+ (74.59) with a BUY signal, but investors should weigh short-term momentum against cash-flow and receivables risks. Monitor earnings on 26 May 2026, contract announcements, and follow-through volume in regular trading before adjusting position size. This analysis uses Meyka AI’s market tools and models; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.